<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-27T14:37:33Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/62264" metadataPrefix="rdf">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/62264</identifier><datestamp>2025-02-19T12:06:23Z</datestamp><setSpec>com_10324_1134</setSpec><setSpec>com_10324_931</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_1213</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
<ow:Publication rdf:about="oai:uvadoc.uva.es:10324/62264">
<dc:title>L-Arginine and beetroot extract supplementation in the prevention of sarcopenia</dc:title>
<dc:creator>Córdova Martínez, Alfredo</dc:creator>
<dc:creator>Caballero García, Alberto</dc:creator>
<dc:creator>Bello Gutierrez, Hugo José</dc:creator>
<dc:creator>Pons Biescas, Antoni</dc:creator>
<dc:creator>Noriega González, David César</dc:creator>
<dc:creator>Roche Collado, Enrique</dc:creator>
<dc:subject>Aging</dc:subject>
<dc:subject>Envejecimiento</dc:subject>
<dc:subject>Creatine kinase</dc:subject>
<dc:subject>Creatine</dc:subject>
<dc:subject>Clinical nutrition</dc:subject>
<dc:subject>Nutrición clínica</dc:subject>
<dc:subject>Nutrition</dc:subject>
<dc:subject>L-arginine</dc:subject>
<dc:subject>Suplementos nutritivos</dc:subject>
<dc:subject>Nitrate</dc:subject>
<dc:subject>Nitratos</dc:subject>
<dc:subject>Muscle strength</dc:subject>
<dc:subject>Fuerza muscular</dc:subject>
<dc:subject>Muscles - Aging</dc:subject>
<dc:subject>Músculos - Envejecimiento</dc:subject>
<dc:subject>Pharmacology</dc:subject>
<dc:description>Producción Científica</dc:description>
<dc:description>Aging is associated with a significant decline in neuromuscular function, leading to a reduction in muscle mass and strength. The aim of the present report was to evaluate the effect of supplementation with nitric oxide precursors (l-arginine and beetroot extract) in muscular function during a training period of 6 weeks in elderly men and women. The study (double-blind, placebo-controlled) involved 66 subjects randomly divided into three groups: placebo, arginine-supplemented and beetroot extract-supplemented. At the end of this period, no changes in anthropometric parameters were observed. Regarding other circulating parameters, urea levels were significantly (p &lt; 0.05) lower in women of the beetroot-supplemented group (31.6 ± 5.9 mg/dL) compared to placebo (41.3 ± 8.5 mg/dL) after 6 weeks of training. In addition, the circulating creatine kinase activity, as an index of muscle functionality, was significantly (p &lt; 0.05) higher in women of the arginine- (214.1 ± 162.2 mIU/L) compared to the beetroot-supplemented group (84.4 ± 36.8 mIU/L) at the end of intervention. No significant effects were noticed with l-arginine or beetroot extract supplementation regarding strength, endurance and SPPB index. Only beetroot extract supplementation improved physical fitness significantly (p &lt; 0.05) in the sprint exercise in men after 6 weeks (2.33 ± 0.59 s) compared to the baseline (2.72 ± 0.41 s). In conclusion, beetroot seems to be more efficient during short-term training while supplementing, preserving muscle functionality in women (decreased levels of circulating creatine kinase) and with modest effects in men.</dc:description>
<dc:date>2023-10-24T13:02:54Z</dc:date>
<dc:date>2023-10-24T13:02:54Z</dc:date>
<dc:date>2022</dc:date>
<dc:type>info:eu-repo/semantics/article</dc:type>
<dc:identifier>Pharmaceuticals, 2022, Vol. 15, Nº. 3, 290</dc:identifier>
<dc:identifier>1424-8247</dc:identifier>
<dc:identifier>https://uvadoc.uva.es/handle/10324/62264</dc:identifier>
<dc:identifier>10.3390/ph15030290</dc:identifier>
<dc:identifier>290</dc:identifier>
<dc:identifier>3</dc:identifier>
<dc:identifier>Pharmaceuticals</dc:identifier>
<dc:identifier>15</dc:identifier>
<dc:identifier>1424-8247</dc:identifier>
<dc:language>eng</dc:language>
<dc:relation>https://www.mdpi.com/1424-8247/15/3/290</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
<dc:rights>© 2022 The Authors</dc:rights>
<dc:rights>Atribución 4.0 Internacional</dc:rights>
<dc:publisher>MDPI</dc:publisher>
<dc:peerreviewed>SI</dc:peerreviewed>
</ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>